Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Next Previous
X
Search
Trial Profile

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandefitemcel (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ACTISSIMA
  • Sponsors SanBio

    • Most Recent Events

    • 14 Sep 2020 According to a SanBio media release, details of the additional analysis results will be announced at the financial results briefing for institutional investors and the media held on 15th Sep 2020.
    • 14 Sep 2020 New analytical results from this Phase 2b clinical trial presented in a SanBio media release.
    • 13 Dec 2019 According to a Sumitomo Dainippon Pharma media release, based on a detailed analysis of the Phase 2b study results and discussions of SB623 future development strategy that followed, the SanBio and Sumitomo Dainippon Pharma concurred that the agreement should be terminated. the SanBio Group will continue development of SB623 for chronic stroke.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top